XLO Xilio Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 12, 2026
$9.01
· of 52w range
· above low
· to high
$0.5052w low
$9.9052w high
Market Cap (MRQ)
$59M
P/E (TTM)
-1.9
EPS (TTM)
$-4.76
Revenue (TTM)
$64M
your badges
52W Range
$1–$10
Analyst Rating
STRONG BUY
Price Target
$20
P/E
-1.9
ROE
-55.0%
Net Profit Margin
-34.1%
Your badge strip is empty — pin a metric anywhere on this page.
XLO Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$9.01
Market Cap (MRQ)
$59M
P/E (TTM)
-1.9
EPS (TTM)
$-4.76
Revenue (TTM)
$64M
ROE (TTM)
-55.0%
52W Range
$1–$10
XLO Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| March 16, 2026 | 1-for-14 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$44M2024-12-31 → 2025-12-31
EPS$-4.192020-12-31 → 2025-12-31
Free Cash Flow$-6M2021-12-31 → 2025-12-31
Net margin-34.1%2024-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | XLO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -1.95Y avg ≈-0.5 | ≈-0.5 | · | · | |
| P/S (TTM) | 0.9 | · | 56.2 | Undervalued | |
| P/B (MRQ) | 0.85Y avg ≈1.3 | ≈1.3 | 3.5 | Undervalued | |
| Price / FCF (TTM) | -1.05Y avg ≈-2.1 | ≈-2.1 | · | · | |
| Price / Cash Flow (TTM) | -1.05Y avg ≈-2.2 | ≈-2.2 | · | · | |
| Price / Tangible Book | 1.25Y avg ≈1.2 | ≈1.2 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | XLO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -48.9% | · | -728.4% | Top tier | |
| EBITDA Margin (TTM) | -46.9% | · | -728.4% | Top tier | |
| Pretax Margin | -80.0% | · | -622.2% | Top tier | |
| Net Profit Margin (TTM) | -34.1% | · | -939.0% | Top tier | |
| ROA (TTM) | -15.2%5Y avg ≈-63.8% | ≈-63.8% | -105.8% | Top tier | |
| ROE (TTM) | -55.0%5Y avg ≈-237.0% | ≈-237.0% | -168.9% | In line | |
| ROIC | -119.0% | · | -128.9% | In line |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | XLO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 4.35Y avg ≈5.9 | ≈5.9 | 3.8 | Strong liquidity | |
| Quick Ratio | 2.45Y avg ≈5.7 | ≈5.7 | 3.5 | In line |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | XLO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 589.9% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | XLO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.4 | · | 0.0 | Top tier | |
| Revenue / Employee | ≈$575.9K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-13.1%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-0.33 | $-0.60 | 44.6% | |
| March 31, 2026 | May 8, 2026 | $-0.58 | $-0.67 | 13.0% |
| Dec. 31, 2025 | $0.81 | $-1.70 | 147.7% | |
| Sept. 30, 2025 | $-0.08 | $-0.42 | 80.2% | |
| June 30, 2025 | $-2.24 | $-1.13 | -98.0% | |
| March 31, 2025 | $-2.52 | $1.34 | -287.6% | |
| Dec. 31, 2024 | $-2.80 | $-3.06 | 8.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Revenue | $44M | $6M | |
| R&D Expense | $56M | $41M | |
| SG&A Expense | $30M | $25M | |
| Operating Expenses | $86M | $67M | |
| Operating Income | $-42M | $-61M | |
| Other Non-op | $1M | $2M | |
| Pretax Income | $-35M | $-58M | |
| Income Tax | $0 | $0 | |
| Net Income | $-35M | $-58M | |
| EPS (Basic) | $-4.19 | $-15.24 | |
| EPS (Diluted) | $-4.19 | $-15.24 | |
| Shares (Basic) | 8,359,109 | 3,822,244 | |
| EBITDA | $-40M | $-59M |
Balance Sheet
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $138M | $55M | |
| Prepaid Expense | $2M | $5M | |
| Current Assets | $145M | $60M | |
| PP&E (Net) | $4M | $4M | |
| PP&E (Gross) | $13M | $12M | |
| Accum. Depreciation | $9M | $7M | |
| Total Assets | $155M | $71M | |
| Accounts Payable | $3M | $3M | |
| Accrued Liabilities | $12M | $10M | |
| Current Liabilities | $56M | $27M | |
| Capital Leases | $6M | $7M | |
| Total Liabilities | $119M | $53M | |
| Common Stock | $0 | $5.0K | |
| Paid-in Capital | $454M | $401M | |
| Retained Earnings | $-419M | $-384M | |
| Stockholders' Equity | $35M | $18M | |
| Liabilities + Equity | $155M | $71M | |
| Shares Outstanding | 4,530,641 | 3,268,299 |
Cash Flow
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| D&A | $2M | $2M | |
| Stock-based Comp | $7M | $6M | |
| Restructuring | · | $937.0K | |
| Other Non-cash | $22M | $32M | |
| Operating Cash Flow | $-5M | $-18M | |
| CapEx | $518.0K | $36.0K | |
| Investing Cash Flow | $-518.0K | $-36.0K | |
| Financing Cash Flow | $88M | $29M | |
| Net Change in Cash | $82M | $11M | |
| Free Cash Flow | $-6M | $-18M |
Profitability
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Operating Margin | -95.9% | -955.0% | |
| Net Margin | -80.0% | -918.1% | |
| Pretax Margin | -80.0% | · | |
| EBITDA Margin | -92.4% | -929.0% | |
| ROA | -31.0% | -88.2% | |
| ROE | -165.5% | -302.0% | |
| ROIC | -119.0% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 2.6 | 2.2 | |
| Quick Ratio | 2.4 | 2.0 |
Efficiency
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 |
Per Share
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Book Value / Share | $7.79 | $0.38 | |
| Cash / Share | $30.36 | $1.21 | |
| EPS (TTM) | $-4.19 | $-15.24 |
Growth Rates
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Revenue YoY | 589.9% | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $44M | $6M | |
| Net Income TTM | $-35M | $-58M | |
| Market Cap | $3M | $44M | |
| P/E | -0.2 | -0.1 | |
| P/S | 0.1 | 6.9 | |
| P/B | 0.1 | 2.5 | |
| P / Tangible Book | 0.1 | 2.5 | |
| P / Cash Flow | -0.6 | -2.4 | |
| P / FCF | -0.5 | -2.4 | |
| Earnings Yield | -654.7% | -1595.8% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $13M | $14M | $19M | $8M | $3M | $2M | $2M | $2M | |
| R&D Expense | $15M | $20M | $18M | $14M | $15M | $8M | $9M | $11M | $11M | |
| SG&A Expense | $8M | $7M | $7M | $7M | $7M | $9M | $7M | $6M | $6M | |
| Operating Expenses | $22M | $27M | $26M | $21M | $22M | $17M | $15M | $17M | $17M | |
| Operating Income | $-3M | $-14M | $-12M | $-2M | $-14M | $-14M | $-14M | $-15M | $-15M | |
| Other Non-op | $1M | $1M | $921.0K | $1M | $-1M | $586.0K | $536.0K | $742.0K | $779.0K | |
| Net Income | $-6M | $-10M | $10M | $-16M | $-16M | $-13M | $-13M | $-14M | $-14M | |
| EPS (Basic) | $-0.33 | $-0.58 | $-3.74 | $-0.11 | $-2.30 | $-2.49 | $-14.16 | $-0.22 | $-0.24 | |
| EPS (Diluted) | $-0.33 | $-0.58 | $-3.74 | $-0.11 | $-2.30 | $-2.49 | $-14.16 | $-0.22 | $-0.24 | |
| Shares (Basic) | 19,404,688 | 16,347,538 | · | 144,106,869 | 6,889,119 | 5,335,740 | · | 63,465,063 | 57,760,178 | |
| EBITDA | $-3M | · | · | $-2M | $-14M | $-13M | · | $-15M | $-15M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $136M | $150M | $138M | $104M | $122M | $89M | $55M | $61M | $75M | |
| Prepaid Expense | $3M | $4M | $2M | $3M | $2M | $4M | $5M | $2M | $3M | |
| Current Assets | $145M | $154M | $145M | $124M | $124M | $93M | $60M | $63M | $78M | |
| PP&E (Net) | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $5M | |
| PP&E (Gross) | $13M | $13M | $13M | $12M | $12M | $12M | $12M | $12M | $12M | |
| Accum. Depreciation | $9M | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $7M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | $92.0K | |
| Total Assets | $154M | $163M | $155M | $134M | $134M | $104M | $71M | $75M | $90M | |
| Accounts Payable | $2M | $1M | $3M | $2M | $4M | $2M | $3M | $972.0K | $1M | |
| Accrued Liabilities | $8M | $9M | $12M | $9M | $6M | $4M | $10M | $10M | $10M | |
| Current Liabilities | $34M | $43M | $56M | $56M | $53M | $48M | $27M | $38M | $39M | |
| Capital Leases | $5M | $5M | $6M | $6M | $6M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $82M | $91M | $119M | $142M | $127M | $93M | $53M | $54M | $56M | |
| Common Stock | $1.0K | $1.0K | · | $5.0K | $5.0K | $5.0K | · | $4.0K | $4.0K | |
| Paid-in Capital | $507M | $501M | $454M | $421M | $420M | $408M | $401M | $392M | $390M | |
| Retained Earnings | $-435M | $-428M | $-419M | $-429M | $-413M | $-397M | $-384M | $-371M | $-357M | |
| Stockholders' Equity | $72M | $73M | $35M | $-8M | $7M | $11M | $18M | $21M | $33M | |
| Liabilities + Equity | $154M | $163M | $155M | $134M | $134M | $104M | $71M | $75M | $90M | |
| Shares Outstanding | 6,580,149 | 5,782,536 | 4,530,641 | 51,829,013 | 51,827,910 | 51,775,264 | 3,268,299 | 43,958,074 | 43,951,922 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $331.0K | $344.0K | $323.0K | $340.0K | $381.0K | $497.0K | $376.0K | $380.0K | $445.0K | |
| Stock-based Comp | $2M | $2M | $3M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Restructuring | · | · | · | · | · | · | $0 | $-41.0K | $30.0K | |
| Other Non-cash | · | · | · | · | · | $40M | · | · | · | |
| Operating Cash Flow | $-19M | $-22M | $-2M | $-17M | $-14M | $29M | $-14M | $-14M | $20M | |
| CapEx | $19.0K | $556.0K | $95.0K | $0 | $401.0K | $22.0K | $6.0K | $9.0K | · | |
| Investing Cash Flow | $-19.0K | $-556.0K | $-95.0K | $0 | $-401.0K | $-22.0K | $-6.0K | $-9.0K | · | |
| Financing Cash Flow | $4M | $36M | $36M | $-285.0K | $47M | $5M | $8M | $-3.0K | $20M | |
| Net Change in Cash | $-14M | $13M | $34M | $-18M | $32M | $34M | $-6M | $-14M | $40M | |
| Free Cash Flow | · | · | · | · | · | $29M | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18.7% | · | · | -10.1% | -177.7% | -472.7% | · | -652.3% | -623.8% | |
| Net Margin | -34.1% | · | · | -85.4% | -196.0% | -452.7% | · | -619.5% | -590.8% | |
| EBITDA Margin | -18.7% | · | · | -10.1% | -177.7% | -455.8% | · | -652.3% | -623.8% | |
| ROA | -4.4% | · | · | -15.6% | -14.2% | -14.2% | · | -18.4% | -15.3% | |
| ROE | -16.1% | · | · | -252.9% | -78.3% | -72.8% | · | -38.2% | -27.6% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.3 | · | · | 2.2 | 2.3 | 2.0 | · | 1.7 | 2.0 | |
| Quick Ratio | 4.0 | 3.5 | · | 1.8 | 2.3 | 1.9 | · | 1.6 | 1.9 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $10.98 | · | · | $-0.16 | $0.14 | $0.21 | · | $0.48 | $0.76 | |
| Cash / Share | $20.67 | · | · | $2.00 | $2.35 | $1.72 | · | $1.39 | $1.71 | |
| EPS (TTM) | $-4.76 | $-5.48 | · | $-19.06 | $-19.17 | $-17.11 | · | $-1.72 | $-2.11 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $64M | $43M | · | $32M | $15M | $9M | · | · | · | |
| Net Income TTM | $-22M | $-55M | · | $-58M | $-56M | $-54M | · | $-63M | $-66M | |
| Market Cap | $63M | · | · | $44M | $35M | $37M | · | $35M | $42M | |
| P/E | -2.0 | -1.5 | · | -0.0 | -0.0 | -0.0 | · | -0.5 | -0.4 | |
| P/S | 1.0 | · | · | 1.4 | 2.3 | 4.0 | · | · | · | |
| P/B | 0.9 | · | · | -5.4 | 5.0 | 3.5 | · | 1.7 | 1.2 | |
| P / Tangible Book | 0.9 | 0.7 | · | · | 5.0 | 3.5 | · | 1.7 | 1.2 | |
| P / Cash Flow | · | · | · | · | · | 1.3 | · | · | · | |
| Earnings Yield | -49.7% | -65.2% | · | -2261.0% | -2819.1% | -2363.3% | · | -218.3% | -222.6% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $44M | $6M | · | · | · |
| Operating Margin % | -95.9% | -955.0% | · | · | · |
| Net Income | $-35M | $-58M | $-76M | $-88M | $-76M |
| Diluted EPS | $-4.19 | $-15.24 | $-2.78 | $-3.22 | $-13.52 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | · | · | 0.1 | · | · |
| Current Ratio | 2.6 | 2.2 | 3.0 | · | 15.8 |
| Quick Ratio | 2.4 | 2.0 | 2.8 | · | 15.5 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-6M | $-18M | $-69M | · | $-82M |
Institutional owners (13F) 3 filers · $8.3M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
3
Value held
$8.3M
New positions
0
Exited positions
0
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 0 (0 vs prior Q) | 0 (-35 vs prior Q) | 0 (0 vs prior Q) | 0 (-1 vs prior Q) | 0 |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | $6,230,727 | 650,389 | 75.27% | Shares |
| TAKEDA PHARMACEUTICAL CO LTD | $1,243,084 | 1,475,121 | 15.02% | Shares |
| VANGUARD GROUP INC | $803,643 | 1,255,692 | 9.71% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | Nov. 5, 2021 | · | Initial filing | Passive investment | SEC |
| SV7 Impact Medicine Fund LP, SV7 (IMF) GP LLP | Nov. 3, 2021 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 27 insiders · 8 officers · 13 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Rene Russo | PRESIDENT AND CEO | Jan. 1, 2026 M | 325,422 | 0 | 0 | $0 |
| Christopher James Frankenfield | Chief Financial Officer | Jan. 1, 2026 M | 24,766 | 0 | 1 | $-4,499 |
| Salvatore Giovine | CHIEF FINANCIAL OFFICER | Feb. 22, 2022 A | · | 0 | 0 | $0 |
| Martin H. Huber Jr. | PRESIDENT AND HEAD OF R&D | Aug. 16, 2023 A | · | 0 | 0 | $0 |
| Yariv Houvras | CHIEF MEDICAL OFFICER | Oct. 1, 2026 A | · | 0 | 0 | $0 |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | Jan. 1, 2026 M | 33,250 | 0 | 0 | $0 |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Jan. 1, 2026 M | 6,371 | 0 | 1 | $-1,169 |
| Edward C English | PRINCIPAL ACCOUNTING OFFICER | Jan. 1, 2023 A | · | 0 | 0 | $0 |
| Akintunde Olatokumbo Bello | Director | June 11, 2026 A | · | 0 | 0 | $0 |
| Daniel J. Curran | Director | June 11, 2026 A | · | 0 | 0 | $0 |
| Yuan Xu | Director | June 11, 2026 A | · | 0 | 0 | $0 |
| Robert W. Ross | Director | June 11, 2026 A | · | 0 | 0 | $0 |
| Aoife Brennan | Director | June 11, 2026 A | · | 0 | 0 | $0 |
| Sara Bonstein | Director | June 11, 2026 A | · | 0 | 0 | $0 |
| James Samuel Shannon | Director | June 11, 2026 A | 10,000 | 1 | 0 | $43,950 |
| Cheryl R Blanchard | Director | April 15, 2026 A | · | 0 | 0 | $0 |
| Christina Rossi | Director | June 11, 2025 A | · | 0 | 0 | $0 |
| Paul J Clancy | Director | June 11, 2025 A | · | 0 | 0 | $0 |
| Tomas J. Heyman | Director | June 12, 2023 A | · | 0 | 0 | $0 |
| Michael Jay Ross | Director | June 15, 2022 A | · | 0 | 0 | $0 |
| Gilead Sciences, Inc. | 10% owner | Feb. 13, 2026 P | 9,105,451 | 1 | 0 | $1,981,670 |
| Merck KGaA | 10% owner | Oct. 26, 2021 C | 680,825 | 0 | 0 | $0 |
| RiverVest Venture Fund IV, L.P. | 10% owner | Oct. 26, 2021 C | 1,441,444 | 0 | 0 | $0 |
| Alexandria Venture Investments, LLC | 10% owner | Oct. 26, 2021 C | 166,423 | 0 | 0 | $0 |
| BAY CITY CAPITAL LLC | 10% owner | Oct. 26, 2021 C | 1,129,490 | 0 | 0 | $0 |
| FIL Ltd | · | Oct. 26, 2021 C | 218,705 | 0 | 0 | $0 |
| FMR LLC | · | Oct. 26, 2021 C | 4,465 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 3 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
XLO Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 5 analysts
BUY
Median target
$20.00
+122.0%
2 40.0%
Strong Buy
2 40.0%
Buy
1 20.0%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
1 analysts · 2026-10-02Mean target $20.00 +122.0%
Low$20.00
Mean$20.00
High$20.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| XLO | $3M | -0.2 | 589.9% | -80.0% | -165.5% | · |
| ACET | · | -0.5 | · | · | · | · |
| BOLD | $27M | -0.5 | · | · | -46.7% | · |
| KLRS | $193M | -3.0 | · | · | -65.8% | · |
| CNTB | $159M | -2.8 | -99.8% | -86687.5% | -97.9% | · |
| CLNN | $64M | · | -41.5% | -13086.5% | 200.2% | · |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | · |
| EXOZ | $92M | -10.0 | · | · | -172.3% | · |
| CELU | $32M | -0.3 | -51.0% | -345.4% | 288.6% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 12, 2026